An interventional study of Precision Diabetes Education (PDE) in Type 2 Diabetes Mellitus (T2DM), sponsored by Taiwanese Association of Diabetes Educators. Completed at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Taiwanese Association of Diabetes Educators · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan — 36 open to participants now, 41 under way, 14 of them phase 3. Diabetes Mellitus, Type 2 · Taiwan.
Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, this one is the 162nd largest by enrollment of the 244 interventional ones that give a count, is one of 10 that started in 2024, is one of 56 with no phase, and was the 275th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,410 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →36 of the 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Taiwan, United States, Brazil and 7 more countries
Ages 18+
AstraZeneca · Sites in Taiwan, United States, Argentina and 13 more countries
Ages 18+
Novo Nordisk A/S · Sites in Taiwan, United States, Argentina and 7 more countries
Ages 10–18
Eli Lilly and Company · Sites in Taiwan, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Taiwan, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
277 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 23 · Phase 3 134 · Phase 4 31
First in 1998; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 80 across 8,356 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 436 across the 244 interventional studies, 1,120 across the 33 observational. Of the 206 that completed or were terminated, 124 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
185 of 277 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Taiwanese Association of Diabetes Educators as lead sponsor.
Taiwanese Association of Diabetes Educators has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07609290Chimei Medical CenterEffects of Exercise Snacks on Clinical and Health Outcomes | 2026-12-31 |
| NCT07642830Chang Gung Memorial HospitalDigital Health Solutions for Patients With Type 2 Diabetes | 2027-01-04 |
| NCT07103460National Taipei University of Nursing and Health SciencesEssential Oil-Assisted Respiratory Training in Type 2 Diabetic Patients With Lung Infections | 2027-07-25 |
| NCT06278207BayerAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | 2027-09-30 |
| NCT07684690National Taiwan University HospitalAI-Assisted Antidiabetic Drug Consultation System for Glycemic Control in Type 2 Diabetes Patients Managed by Non-Specialist Physicians | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter interventional study evaluated the implementation of precision diabetes education guided by individualized diabetes complication risk assessment in adults with type 2 diabetes. The study was conducted at six hospitals in Taiwan.
Participants underwent assessment of their predicted risks for six major diabetes-related complications: diabetic kidney disease, atherosclerotic cardiovascular disease, congestive heart failure, ischemic stroke, diabetic retinopathy, and lower-extremity amputation. Diabetes educators used the risk assessment results to identify the complication with the highest predicted risk and to provide individualized education focused on prevention and modification of relevant health behaviors. Participants continued to receive standard diabetes education and routine clinical care. Personalized education was provided at enrollment and again during follow-up, with clinical information, complication-risk assessment, and patient-reported measures collected during the 6-month study period.
The study aimed to establish a personalized diabetes education model based on complication-risk assessment and to improve the quality of diabetes complication prevention and care.
The study was part of the Precision Diabetes Education program coordinated by the Taiwanese Association of Diabetes Educators and conducted at six participating hospitals in Taiwan. The first part of the study used a prospective, single-group interventional design with a 6-month follow-up period.
After providing written informed consent, participants underwent collection of demographic, clinical, laboratory, medication, and health-behavior information. These data were entered into a diabetes complication risk assessment model developed by investigators from the National Health Research Institutes, Kaohsiung Medical University Hospital, and National Chengchi University. The model estimated individualized absolute and relative risks for six diabetes-related complications: diabetic kidney disease, atherosclerotic cardiovascular disease, congestive heart failure, ischemic stroke, diabetic retinopathy, and lower-extremity amputation.
Based on the risk assessment results, diabetes educators used a standardized education manual to provide individualized education focused primarily on the complication with the highest predicted risk. Participants also continued to receive standard diabetes education and routine clinical care. Personalized education was provided at enrollment and repeated approximately 3 months later. At 6 months, complication-risk assessment, clinical measurements, laboratory data, medication information, and patient-reported measures were reassessed.
The original study protocol did not specify a hierarchy of primary and secondary outcome measures. For retrospective registration, change in hemoglobin A1c from baseline to 6 months was designated as the registry primary outcome; the other outcomes listed in the original protocol are reported as other pre-specified outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants underwent individualized diabetes complication risk assessment and received personalized diabetes education based primarily on the complication with the highest predicted risk. Standard diabetes education and routine clinical care were continued throughout the study. Personalized education was provided at enrollment and repeated approximately 3 months later, with reassessment at 6 months.
Behavioral: Precision Diabetes Education (PDE)
Participants underwent individualized risk assessment for six major diabetes-related complications: diabetic kidney disease, atherosclerotic cardiovascular disease, congestive heart failure, ischemic stroke, diabetic retinopathy, and lower-extremity amputation. Based on the predicted risk profile, diabetes educators used a standardized education manual to provide personalized education focused primarily on the complication with the highest predicted risk and relevant modifiable health behaviors. Participants continued to receive standard diabetes education and routine clinical care. Personalized education was provided at enrollment and repeated approximately 3 months later. At 6 months, complication-risk assessment and relevant clinical and patient-reported measures were reassessed.
Change From Baseline in Hemoglobin A1c
Change in hemoglobin A1c from baseline to the 6-month assessment, expressed in percentage points.
Time frame: Baseline and Month 6
Change From Baseline in Systolic Blood Pressure
Change in systolic blood pressure from baseline to the 6-month assessment, expressed in mmHg.
Time frame: Baseline and Month 6
Change From Baseline in Diastolic Blood Pressure
Change in diastolic blood pressure from baseline to the 6-month assessment, expressed in mmHg.
Time frame: Baseline and Month 6
Change From Baseline in Body Weight
Change in body weight from baseline to the 6-month assessment, expressed in kilograms.
Time frame: Baseline and Month 6
Change From Baseline in Total Cholesterol
Change in serum total cholesterol from baseline to the 6-month assessment, expressed in mg/dL.
Time frame: Baseline and Month 6
Change From Baseline in Low-Density Lipoprotein Cholesterol
Change in serum low-density lipoprotein cholesterol from baseline to the 6-month assessment, expressed in mg/dL.
Time frame: Baseline and Month 6
Change From Baseline in High-Density Lipoprotein Cholesterol
Change in serum high-density lipoprotein cholesterol from baseline to the 6-month assessment, expressed in mg/dL.
Time frame: Baseline and Month 6
Change From Baseline in Triglycerides
Change in serum triglyceride concentration from baseline to the 6-month assessment, expressed in mg/dL.
Time frame: Baseline and Month 6
Change From Baseline in Serum Creatinine
Change in serum creatinine from baseline to the 6-month assessment, expressed in mg/dL.
Time frame: Baseline and Month 6
Change From Baseline in Urinary Albumin-to-Creatinine Ratio
Change in urinary albumin-to-creatinine ratio from baseline to the 6-month assessment, expressed in mg/g.
Time frame: Baseline and Month 6
Change From Baseline in Medication Adherence Score
Change in the 6-item self-reported medication adherence score from baseline to Month 6. Total scores range from 0 to 12, with higher scores indicating better medication adherence.
Time frame: Baseline and Month 6
Change From Baseline in Diabetes-Related Emotional Distress
Change in the 8-item Problem Areas in Diabetes Short Form (PAID-SF-8) score from baseline to Month 6. Total scores range from 0 to 32, with higher scores indicating greater diabetes-related emotional distress.
Time frame: Baseline and Month 6
Change From Baseline in Dietary Quality Score
Change in the study-specified 10-item dietary quality score from baseline to Month 6. Total scores range from 10 to 50, with lower scores indicating healthier dietary behaviors.
Time frame: Baseline and Month 6
Change From Baseline in Neuropathic Pain Score
Change in Douleur Neuropathique 4 (DN4) score from baseline to Month 6. Total scores range from 0 to 10, with higher scores indicating a greater burden of neuropathic pain symptoms.
Time frame: Baseline and Month 6
Plan to share: No — Individual participant data will not be shared because the original study protocol did not include a plan for external IPD sharing. Study findings may be reported in aggregate form.
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Feb 2025, 11 months.
Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 11 months is below that.
Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.